



(11) **EP 1 558 615 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

**Corrected version no 1 (W1 B1)**

**Bibliography INID code(s) 84**

(51) Int Cl.:

**C07D 473/30** <sup>(2006.01)</sup> **C07D 473/34** <sup>(2006.01)</sup>

**C07D 473/40** <sup>(2006.01)</sup> **C07D 239/48** <sup>(2006.01)</sup>

**A61K 31/52** <sup>(2006.01)</sup> **A61P 3/04** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**10.10.2007 Bulletin 2007/41**

(86) International application number:

**PCT/IB2003/004619**

(45) Date of publication and mention  
of the grant of the patent:

**29.08.2007 Bulletin 2007/35**

(87) International publication number:

**WO 2004/037823 (06.05.2004 Gazette 2004/19)**

(21) Application number: **03751149.0**

(22) Date of filing: **21.10.2003**

(54) **PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS**

PURINDERIVATE UND IHRE VERWENDUNG ALS LIGANDEN DES CANNABINOID REZEPTORS

COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES  
CANNABINOIDES

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

**AL LT LV MK**

(74) Representative: **Motion, Keith Robert**

**Pfizer Limited**

**Patents Department**

**Ramsgate Road**

**Sandwich,**

**Kent CT13 9NJ (GB)**

(30) Priority: **28.10.2002 US 421874 P**

(43) Date of publication of application:

**03.08.2005 Bulletin 2005/31**

(56) References cited:

**EP-A- 1 054 012**

**US-A- 5 256 398**

(73) Proprietor: **Pfizer Products Inc.**

**Groton, CT 06340 (US)**

- **PERTWEE G. R.: "Cannabinoid receptor ligands"**  
**EXP. OPIN. INVEST. DRUGS**, vol. 9, no. 7, 2000,  
pages 1553-1571, XP009024282 cited in the  
application

(72) Inventor: **GRIFFITH, David A.,**

**Pfizer Global Research and Development**

**Groton, CT 06340 (US)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 558 615 B8**